Global Dermatology Drugs Market Segmentation, By Dermatological Diseases (Acne, Dermatitis, Psoriasis, Skin Cancer, Others), Prescription mode (Prescription Based Drugs, Over Counter Drugs), Drug Classification (Corticosteroids, Astringents, Anti-Inflammatory & Antipruritic Drugs, Anti-Infective/Antibacterial Drugs, Antifungal Drugs), Route Of Administration (Topical, Oral, Parenteral Administration), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Speciality Clinics, Cosmetic Centres) – Industry Trends and Forecast to 2031.
Dermatology Drugs Market Analysis
The global dermatology drugs market is expected to witness significant growth during the forecast period. The global dermatological drugs market is expected to grow due to driving factors such as the availability of medical resources for detecting and treating skin diseases is expected to see rise in the market growth. COVID-19 also had an impact on the market growth.
Dermatology Drugs Market Size
Global dermatology drugs Market size was valued at USD 20.79 million in 2023 and is projected to reach USD 45.37 billion by 2031, with a CAGR of 10.25% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes
|
Dermatology Drugs Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
LUPIN (India), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi (France), Amgen inc. (U.S.), Lilly (U.S.), AstraZeneca (U.K.), AbbVie Inc (U.S.), Johnson & Johnson Private Limited (U.S.), LEO Pharma A/S (Denmark), Merck & Co., Inc (U.S.), Bausch Health Companies Inc (Canada) and Bristol-Myers Squibb Company (U.S.)
|
|
Market Opportunities
|
|
Dermatology Drugs Market Definition
Dermatology is a therapy area dealing with skin, hair, and nails diseases, where the most common conditions are psoriasis, eczema, and acne vulgaris. Dermatology drugs are used to manage and treat diseases related to skin, nail, hair, and genital membranes.
Dermatology Drugs Market Dynamics
Drivers
- Rise in Clinical Studies
The dermatologicals market is expected to rise as more clinical studies are conducted to assess the efficacy and safety of a variety of medicinal medications. For instance, the pharmaceutical company Amgen Inc. announced the favourable findings of a phase 3 placebo-controlled, double-blind clinical research in December 2021. The trial's objective is to evaluate Otezla's effectiveness in managing moderate to severe psoriasis.
Opportunities
- Increasing Elderly Population
The development of the dermatological pharmaceuticals market is fueled by the loss of human skin's ability to function properly with ageing, leading to numerous skin illnesses. Additionally, as we age, the body begins to experience several additional issues, including slower wound healing, increased sensitivity to ultraviolet (UV) radiation, increased susceptibility to infections, and decreased subcutaneous fat. Due to the increased likelihood of numerous skin conditions, the need for dermatological medications has skyrocketed.
Restraints/Challenges
- High Cost
The huge expenditure associated with these drugs surely hamper the market growth. Several market players make huge investments in manufacturing new drugs to faster the recovery process; in return, the cost is increased.
This global dermatology drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global dermatology drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Dermatology Drugs Market Scope
The global dermatology drugs market is segmented on the basis of type, technology and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Dermatological Diseases
- Acne
- Dermatitis
- Psoriasis
- Skin Cancer
- Others
Prescription mode
- Prescription Based Drugs
- Over Counter Drugs
Drug Classification
- Corticosteroids
- Astringents
- Anti-Inflammatory & Antipruritic Drugs
- Anti-Infective/Antibacterial Drugs
- Antifungal Drugs
Route of Administration
- Topical
- Oral
- Parenteral Administration
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End-User
- Hospitals
- Speciality Clinics
- Cosmetic Centres
Dermatology Drugs Market Regional Analysis
The global dermatology drugs market is analysed and market size insights and trends are provided by type, technology and end-user as referenced above.
The major countries covered in the global dermatology drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Europe and Asia-Pacific dominate the dermatology drugs market due to rising skin disease awareness, a growing number of patients suffering from acne, vitiligo, and dermatitis, a growing patient pool of a wide range of dermatological conditions, and patients' willingness to pay for expensive medications in these regions.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Dermatology Drugs Market Share
The global dermatology drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global dermatology drugs market
Dermatology Drugs Market Leaders Operating in the Market Are:
- LUPIN (India)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc. (U.S.)
- Sanofi (France)
- Amgen inc. (U.S.)
- Lilly (U.S.)
- AstraZeneca (U.K.)
- AbbVie Inc (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- LEO Pharma A/S (Denmark)
- Merck & Co., Inc (U.S.)
- Bausch Health Companies Inc (Canada)
- Bristol-Myers Squibb Company (U.S.)
Latest Developments in Dermatology Drugs Market
Perrigo Company plc, a leading global provider of quality and affordable self-care products, announced in april 2020 that it acquired three Eastern European OTC skincare and hair loss treatment brands (Emolium, Iwostin, and Loxon) from Sanofi.
SKU-